Type of information: Series C financing round
Company: Orchard Therapeutics (UK)
Investors: ArrowMark Partners (USA - CO) Cormorant Asset Management (USA - MA) Foresite Capital (USA - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) Venrock (USA - CA) Foresite Capital (USA - NY) Sphera Global Healthcare (Spain) Medison Ventures Driehaus Capital Management (USA - IL) Ghost Tree Capital Group (USA - NY) Temasek (Singpore) Baillie Gifford (UK) Cowen Healthcare (USA - NY) Agent Capital (USA - MA)
Amount: $150 Million
Funding type: series C financing round
- Proceeds from the Series C financing will be used to progress Orchard’s three most advanced clinical programs: OTL-101 for adenosine deaminase severe combined immunodeficiency (ADA-SCID), OTL-200 for metachromatic leukodystrophy (MLD) and OTL-103 for Wiskott–Aldrich syndrome (WAS) towards registration and commercialization. The funding will also support the clinical and preclinical development of the company’s rare disease gene therapy pipeline.
- • On August 13, 2018, Orchard Therapeutics announced the completion of an oversubscribed $150 million Series C financing. Deerfield Management led the financing with significant new investments from RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management LP, ArrowMark Partners, Sphera Global Healthcare, Medison Ventures, Driehaus Capital Management and Ghost Tree Capital Group, LP, as well as additional U.S. based healthcare focused funds. Existing investors also participated including Temasek, Baillie Gifford, RTW Investments, LP, Cowen Healthcare Investments and Agent Capital. Cowen served as exclusive placement agent for the financing.
Therapeutic area: Rare diseases - Genetic diseases